ClinicalTrials.gg
CompletedNCT06460493Updated Apr 18, 2025Results posted

Effect of Ensifentrine Treatment on CAT Score

A Phase 3 interventional study of Ensifentrine 3 mg twice daily in COPD, sponsored by Verona Pharma plc. Completed at 1 site in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-18.

Sponsored by Verona Pharma plc (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 2 under way, 1 of them phase 3. ensifentrine · Pulmonary Disease, Chronic Obstructive.

Enrollment
15th of 15
20 · median 79
Started
2024
the only one that year
Phase 3
5 of 15
1 open now
Registered
12th of 15
by date
Lead sponsor
9 of 15
Verona Pharma plc

Among the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive, this one is the 15th largest by enrollment, is the only one that started in 2024, is one of 5 in phase 3, and was the 12th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About ensifentrine

ensifentrine: first FDA approval 2024 (OHTUVAYRE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing ensifentrine in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of this open-label, single center trial is to assess the effect of twice daily nebulized ensifentrine (3 mg) on COPD symptoms measured by the COPD Assessment Test (CAT™) scores over 12 weeks in subjects with symptomatic, moderate to severe COPD, taking maintenance LAMA/LABA or LAMA/LABA/ICS therapy. Subjects will continue the maintenance treatment during study participation.

03

Conditions studied

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of giving .
  • Current or former cigarette smokers with a history of cigarette smoking ≥ 10 pack years.
  • Established clinical history of moderate to severe .
  • Pre- and post-albuterol /FVC ratio of \< 0.70.
  • Post-albuterol FEV1 ≥ 30 % and ≤ 75% of predicted normal.
  • ≥2 on the modified Medical Research Council (mMRC) Dyspnea Scale.
  • ≥10 on the COPD Assessment Test™.
  • Taking stable dual (LAMA+LABA) or triple (LAMA+LABA+ICS) maintenance therapy for at least 8 weeks.
  • Capable of using a standard jet nebulizer and performed spirometry assessment.

Exclusion criteria

Exclusion Criteria:

  1. Hospitalizations for (or COPD exacerbation), pneumonia, or other serious infection or treatment with oral or parenteral (oral, intravenous, or intramuscular) within the past 12 weeks.
  2. Lower respiratory tract infection within the past 6 weeks or an active infection.
  3. History of life-threatening COPD, including Intensive Care Unit admission and/or requiring intubation within 1-year.
  4. Major surgery (requiring general anesthesia) within the past 6 weeks, lack of full recovery from surgery, or planned surgery through the end of the study.
  5. Concomitant pulmonary disease other than COPD (e.g., asthma, tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, interstitial lung diseases, sleep apnea (unless controlled with stable continuous positive airway pressure [CPAP] use), known alpha-1 antitrypsin deficiency, core pulmonale or other non-specific pulmonary disease).
  6. Severe comorbidities including unstable cardiac, (e.g., myocardial infarction within 1 year prior to screening, unstable angina within 6 months, or unstable or life-threatening arrhythmia requiring intervention within 3 months) or any other clinically significant medical conditions including uncontrolled diseases (e.g., endocrine, neurological, hepatic, gastrointestinal, renal, hematological, urological, immunological, psychiatric or ophthalmic diseases) that would, in the opinion of the Investigator, preclude the subject from safely completing the required tests or the study, or is likely to result in disease progression that would require withdrawal of the subject.
  7. infection or other immunodeficiency.
  8. Previous lung resection or lung reduction surgery within 1-year.
  9. Long term oxygen use defined as oxygen therapy prescribed for greater than 12 hours per day.
  10. Pulmonary rehabilitation unless such treatment has been stable for at least 4 weeks and remains stable during the study.
  11. History of or current of any organ system, treated or untreated within the past 5 years, except for localized basal or squamous cell carcinoma of the skin.
  12. Significant psychiatric disease that would likely result in the subject not being able to complete the study, in the opinion of the Investigator.
  13. Findings on physical examination that an investigator considers to be clinically significant.
  14. Known (ALT) ≥ 2 × (ULN), alkaline phosphatase and/or > 1.5 × ULN (isolated bilirubin > 1.5 × ULN is acceptable if fractionated bilirubin \< 35%).
  15. Known diagnosis of severe chronic kidney disease.
  16. Any other known abnormal clinical, cardiac or laboratory (hematology, biochemistry or viral) findings, deemed by an investigator to be clinically significantly abnormal.
  17. Use of prohibited medications, including nebulized medication, within the time intervals.
  18. Current or history of drug or alcohol abuse within the past 5 years.
  19. Women who are breast feeding.
  20. Use of an experimental drug within 30 days or 5 half-lives, whichever is longer, and/or participation in a study treatment-free follow-up phase of a clinical study within 30 days.
  21. Use of an experimental medical device or participation in a follow-up phase of an experimental medical device clinical study within 30 days.
  22. Affiliation with the investigator site, including an Investigator, Sub-Investigator, study coordinator, study nurse, other employee of participating investigator or study site or a family member of the aforementioned.
  23. A disclosed history or one known to the Investigator of significant noncompliance in previous studies or with prescribed medications.
  24. Any other reason that the Investigator considers makes the subject unsuitable to participate.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Ensifentrine

    Inhaled ensifentrine twice daily for 12 weeks via standard jet nebulizer in addition to standard dual (LAMA/LABA) or triple (LAMA/LABA/ICS) COPD therapy.

    Drug: Ensifentrine 3 mg twice daily

Interventions

06

What researchers measure

Primary outcomes

  1. The Proportion of CAT Score Responders in the Full Analysis Set at Week 12

    Responders are defined as an improvement (decrease) from baseline of ≥2 points. The COPD Assessment Test(tm) (CAT) is a one-page, 8-item questionnaire suitable for completion by patients diagnosed with COPD. When completing the questionnaire, individuals rate their experience on a 6-point scale, ranging from 0 (no impairment) to 5 (maximum impairment) with a scoring range of 0-40. Higher scores indicate greater disease impact. The individual items are: Cough, Mucus, Chest Tight, Breathless, Limited Activities, Confident, Sleep and Energy). CAT was self-completed at baseline, week 6 and week 12.

    Time frame: 12 Weeks

Secondary outcomes

  1. The Proportion of CAT Score Responders in the Full Analysis Set at Week 6

    Responders are defined as an improvement (decrease) from baseline of ≥2 points. The COPD Assessment Test (CAT) is a one-page, 8-item questionnaire suitable for completion by patients diagnosed with COPD. When completing the questionnaire, individuals rate their experience on a 6-point scale, ranging from 0 (no impairment) to 5 (maximum impairment) with a scoring range of 0-40. Higher scores indicate greater disease impact. The individual items are: Cough, Mucus, Chest Tight, Breathless, Limited Activities, Confident, Sleep and Energy). CAT was self-completed at baseline, week 6 and week 12.

    Time frame: 6 Weeks

  2. Mean Change From Baseline - CAT Score in the Full Analysis Set

    The COPD Assessment Test (CAT) is a one-page, 8-item questionnaire suitable for completion by patients diagnosed with COPD. When completing the questionnaire, individuals rate their experience on a 6-point scale, ranging from 0 (no impairment) to 5 (maximum impairment) with a scoring range of 0-40. Higher scores indicate greater disease impact. The individual items are: Cough, Mucus, Chest Tight, Breathless, Limited Activities, Confident, Sleep and Energy). CAT was self-completed at baseline, week 6 and week 12. A decrease from baseline indicates an improvement in COPD symptoms.

    Time frame: At week 6 and week 12

  3. Mean Change From Baseline - CAT Individual Item (1, Cough) in the Full Analysis Set

    The COPD Assessment Test (CAT) is a one-page, 8-item questionnaire suitable for completion by patients diagnosed with COPD. When completing the questionnaire, individuals rate their experience on a 6-point scale, ranging from 0 (no impairment) to 5 (maximum impairment) with a scoring range of 0-40. Higher scores indicate greater disease impact. Question 1: (0) I never cough → (5) I cough all the time. CAT was self-completed at baseline, week 6 and week 12.

    Time frame: At week 6 and week 12

  4. Mean Change From Baseline - CAT Individual Item (2, Mucus) in the Full Analysis Set

    The COPD Assessment Test (CAT) is a one-page, 8-item questionnaire suitable for completion by patients diagnosed with COPD. When completing the questionnaire, individuals rate their experience on a 6-point scale, ranging from 0 (no impairment) to 5 (maximum impairment) with a scoring range of 0-40. Higher scores indicate greater disease impact. Question 2: (0) I have no phlegm (mucus) in my chest at all → (5) My chest is completely full of phlegm (mucus) CAT was self-completed at baseline, week 6 and week 12.

    Time frame: At week 6 and week 12

  5. Mean Change From Baseline - CAT Individual Item (3, Chest Tight) in the Full Analysis Set

    The COPD Assessment Test (CAT) is a one-page, 8-item questionnaire suitable for completion by patients diagnosed with COPD. When completing the questionnaire, individuals rate their experience on a 6-point scale, ranging from 0 (no impairment) to 5 (maximum impairment) with a scoring range of 0-40. Higher scores indicate greater disease impact. Question 3: (0) My chest does not feel tight at all → (5) My chest feels very tight CAT was self-completed at baseline, week 6 and week 12.

    Time frame: At week 6 and week 12

  6. Mean Change From Baseline - CAT Individual Item (4, Breathless) in the Full Analysis Set

    The COPD Assessment Test (CAT) is a one-page, 8-item questionnaire suitable for completion by patients diagnosed with COPD. When completing the questionnaire, individuals rate their experience on a 6-point scale, ranging from 0 (no impairment) to 5 (maximum impairment) with a scoring range of 0-40. Higher scores indicate greater disease impact. Question 4: (0) When I walk up a hill or one flight of stairs I am not breathless → (5) When I walk up a hill or one flight of stairs I am very breathless CAT was self-completed at baseline, week 6 and week 12.

    Time frame: At week 6 and week 12

  7. Mean Change From Baseline - CAT Individual Item (5, Activities) in the Full Analysis Set

    The COPD Assessment Test (CAT) is a one-page, 8-item questionnaire suitable for completion by patients diagnosed with COPD. When completing the questionnaire, individuals rate their experience on a 6-point scale, ranging from 0 (no impairment) to 5 (maximum impairment) with a scoring range of 0-40. Higher scores indicate greater disease impact. Question 5: (0) I am not limited doing any activities at home → (5) I am very limited doing activities at home CAT was self-completed at baseline, week 6 and week 12.

    Time frame: At week 6 and week 12

  8. Mean Change From Baseline - CAT Individual Item (6, Confidence) in the Full Analysis Set

    The COPD Assessment Test (CAT) is a one-page, 8-item questionnaire suitable for completion by patients diagnosed with COPD. When completing the questionnaire, individuals rate their experience on a 6-point scale, ranging from 0 (no impairment) to 5 (maximum impairment) with a scoring range of 0-40. Higher scores indicate greater disease impact. Question 6: (0) I am confident leaving my home despite my lung condition → (5) I am not at all confident leaving my home because of my lung condition CAT was self-completed at baseline, week 6 and week 12.

    Time frame: At week 6 and week 12

  9. Mean Change From Baseline - CAT Individual Item (7, Sleep) in the Full Analysis Set

    The COPD Assessment Test (CAT) is a one-page, 8-item questionnaire suitable for completion by patients diagnosed with COPD. When completing the questionnaire, individuals rate their experience on a 6-point scale, ranging from 0 (no impairment) to 5 (maximum impairment) with a scoring range of 0-40. Higher scores indicate greater disease impact. Question 7: (0) I sleep soundly → (5) I don't sleep soundly because of my lung condition CAT was self-completed at baseline, week 6 and week 12.

    Time frame: At week 6 and week 12

  10. Mean Change From Baseline - CAT Individual Item (8, Energy) in the Full Analysis Set

    The COPD Assessment Test (CAT) is a one-page, 8-item questionnaire suitable for completion by patients diagnosed with COPD. When completing the questionnaire, individuals rate their experience on a 6-point scale, ranging from 0 (no impairment) to 5 (maximum impairment) with a scoring range of 0-40. Higher scores indicate greater disease impact. Question 8: (0) I have lots of energy → (5) I have no energy at all CAT was self-completed at baseline, week 6 and week 12.

    Time frame: At week 6 and week 12

Other outcomes

  1. Mean Change From Baseline in Blood Pressure in the Safety Analysis Set

    Vital signs were assessed at baseline, week 6 and week 12. Week 12 is reported. Determine any clinically significant change from baseline in systolic and diastolic blood pressure.

    Time frame: 12 Weeks

  2. Mean Change From Baseline in Pulse Rate in the Safety Analysis Set

    Vital signs were assessed at baseline, week 6 and week 12. Week 12 is reported. Determine any clinically significant change from baseline in pulse rate.

    Time frame: 12 Weeks

07

Results

Posted Apr 18, 2025

Participant flow

Following the informed consent process, screening assessments were completed at visits 1 and 2.

Participant flow — Overall Study
MilestoneEnsifentrine 3 mg BID
Started20
Completed18
Not completed2
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryThe Proportion of CAT Score Responders in the Full Analysis Set at Week 12

Responders are defined as an improvement (decrease) from baseline of ≥2 points. The COPD Assessment Test(tm) (CAT) is a one-page, 8-item questionnaire suitable for completion by patients diagnosed with COPD. When completing the questionnaire, individuals rate their experience on a 6-point scale, ranging from 0 (no impairment) to 5 (maximum impairment) with a scoring range of 0-40. Higher scores indicate greater disease impact. The individual items are: Cough, Mucus, Chest Tight, Breathless, Limited Activities, Confident, Sleep and Energy). CAT was self-completed at baseline, week 6 and week 12.

Time frame:
12 Weeks
Reported as:
Count of participants · Participants
The Proportion of CAT Score Responders in the Full Analysis Set at Week 12
ParticipantsEnsifentrine 3 mg BID
The Proportion of CAT Score Responders in the Full Analysis Set at Week 1212
Statistical analysis
  • Ensifentrine 3 mg BID · Negative binomial regression: 67.0 · 95% CI 38.0 to 100.0A two-sided unadjusted 95% confidence interval for the proportion was used to determine study success with the lower bound of the CI \> 0 indicating success.
SecondaryThe Proportion of CAT Score Responders in the Full Analysis Set at Week 6

Responders are defined as an improvement (decrease) from baseline of ≥2 points. The COPD Assessment Test (CAT) is a one-page, 8-item questionnaire suitable for completion by patients diagnosed with COPD. When completing the questionnaire, individuals rate their experience on a 6-point scale, ranging from 0 (no impairment) to 5 (maximum impairment) with a scoring range of 0-40. Higher scores indicate greater disease impact. The individual items are: Cough, Mucus, Chest Tight, Breathless, Limited Activities, Confident, Sleep and Energy). CAT was self-completed at baseline, week 6 and week 12.

Time frame:
6 Weeks
Reported as:
Count of participants · Participants
The Proportion of CAT Score Responders in the Full Analysis Set at Week 6
ParticipantsEnsifentrine 3 mg BID
The Proportion of CAT Score Responders in the Full Analysis Set at Week 68
Statistical analysis
  • Ensifentrine 3 mg BID · Negative binomial regression: 44.4 · 95% CI 22.0 to 89.5A two-sided unadjusted 95% confidence interval for the proportion was used to determine study success with the lower bound of the CI \> 0 indicating success.
SecondaryMean Change From Baseline - CAT Score in the Full Analysis Set

The COPD Assessment Test (CAT) is a one-page, 8-item questionnaire suitable for completion by patients diagnosed with COPD. When completing the questionnaire, individuals rate their experience on a 6-point scale, ranging from 0 (no impairment) to 5 (maximum impairment) with a scoring range of 0-40. Higher scores indicate greater disease impact. The individual items are: Cough, Mucus, Chest Tight, Breathless, Limited Activities, Confident, Sleep and Energy). CAT was self-completed at baseline, week 6 and week 12. A decrease from baseline indicates an improvement in COPD symptoms.

Time frame:
At week 6 and week 12
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline - CAT Score in the Full Analysis Set
units on a scaleEnsifentrine 3 mg BID
CAT score at week 6 (mean change from baseline)-1.5 (-4.0 to 1.1)
CAT score at week 12 (mean change from baseline)-2.3 (-4.0 to -0.6)
SecondaryMean Change From Baseline - CAT Individual Item (1, Cough) in the Full Analysis Set

The COPD Assessment Test (CAT) is a one-page, 8-item questionnaire suitable for completion by patients diagnosed with COPD. When completing the questionnaire, individuals rate their experience on a 6-point scale, ranging from 0 (no impairment) to 5 (maximum impairment) with a scoring range of 0-40. Higher scores indicate greater disease impact. Question 1: (0) I never cough → (5) I cough all the time. CAT was self-completed at baseline, week 6 and week 12.

Time frame:
At week 6 and week 12
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline - CAT Individual Item (1, Cough) in the Full Analysis Set
units on a scaleEnsifentrine 3 mg BID
CAT question 1 (cough) at week 6 (mean change from baseline)-0.2 (-0.7 to 0.3)
CAT question 1 (cough) at week 12 (mean change from baseline)-0.3 (-0.9 to 0.4)
SecondaryMean Change From Baseline - CAT Individual Item (2, Mucus) in the Full Analysis Set

The COPD Assessment Test (CAT) is a one-page, 8-item questionnaire suitable for completion by patients diagnosed with COPD. When completing the questionnaire, individuals rate their experience on a 6-point scale, ranging from 0 (no impairment) to 5 (maximum impairment) with a scoring range of 0-40. Higher scores indicate greater disease impact. Question 2: (0) I have no phlegm (mucus) in my chest at all → (5) My chest is completely full of phlegm (mucus) CAT was self-completed at baseline, week 6 and week 12.

Time frame:
At week 6 and week 12
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline - CAT Individual Item (2, Mucus) in the Full Analysis Set
units on a scaleEnsifentrine 3 mg BID
CAT question 2 (mucus) at week 6 (mean change from baseline)0.0 (-0.7 to 0.6)
CAT question 2 (mucus) at week 12 (mean change from baseline)-0.5 (-1.1 to 0.0)
Other pre-specifiedMean Change From Baseline in Blood Pressure in the Safety Analysis Set

Vital signs were assessed at baseline, week 6 and week 12. Week 12 is reported. Determine any clinically significant change from baseline in systolic and diastolic blood pressure.

Time frame:
12 Weeks
Reported as:
Mean · mmHg
Mean Change From Baseline in Blood Pressure in the Safety Analysis Set
mmHgEnsifentrine 3 mg BID
Systolic blood pressure at week 12 (mean change from baseline)1.2 ± 15.08
Diastolic blood pressure at week 12 (mean change from baseline)2.8 ± 10.37
Other pre-specifiedMean Change From Baseline in Pulse Rate in the Safety Analysis Set

Vital signs were assessed at baseline, week 6 and week 12. Week 12 is reported. Determine any clinically significant change from baseline in pulse rate.

Time frame:
12 Weeks
Reported as:
Mean · bpm
Mean Change From Baseline in Pulse Rate in the Safety Analysis Set
bpmEnsifentrine 3 mg BID
Mean Change From Baseline in Pulse Rate in the Safety Analysis Set2.9 ± 11.11
SecondaryMean Change From Baseline - CAT Individual Item (3, Chest Tight) in the Full Analysis Set

The COPD Assessment Test (CAT) is a one-page, 8-item questionnaire suitable for completion by patients diagnosed with COPD. When completing the questionnaire, individuals rate their experience on a 6-point scale, ranging from 0 (no impairment) to 5 (maximum impairment) with a scoring range of 0-40. Higher scores indicate greater disease impact. Question 3: (0) My chest does not feel tight at all → (5) My chest feels very tight CAT was self-completed at baseline, week 6 and week 12.

Time frame:
At week 6 and week 12
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline - CAT Individual Item (3, Chest Tight) in the Full Analysis Set
units on a scaleEnsifentrine 3 mg BID
CAT question 3 (chest tight) at week 6 (mean change from baseline)-0.3 (-0.7 to 0.1)
CAT question 3 (chest tight) at week 12 (mean change from baseline)-0.4 (-0.8 to 0.1)
SecondaryMean Change From Baseline - CAT Individual Item (4, Breathless) in the Full Analysis Set

The COPD Assessment Test (CAT) is a one-page, 8-item questionnaire suitable for completion by patients diagnosed with COPD. When completing the questionnaire, individuals rate their experience on a 6-point scale, ranging from 0 (no impairment) to 5 (maximum impairment) with a scoring range of 0-40. Higher scores indicate greater disease impact. Question 4: (0) When I walk up a hill or one flight of stairs I am not breathless → (5) When I walk up a hill or one flight of stairs I am very breathless CAT was self-completed at baseline, week 6 and week 12.

Time frame:
At week 6 and week 12
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline - CAT Individual Item (4, Breathless) in the Full Analysis Set
units on a scaleEnsifentrine 3 mg BID
CAT question 4 (breathless) at week 6 (mean change from baseline)-0.9 (-1.6 to -0.2)
CAT question 4 (breathless) at week 12 (mean change from baseline)-0.5 (-1.0 to 0.0)
SecondaryMean Change From Baseline - CAT Individual Item (5, Activities) in the Full Analysis Set

The COPD Assessment Test (CAT) is a one-page, 8-item questionnaire suitable for completion by patients diagnosed with COPD. When completing the questionnaire, individuals rate their experience on a 6-point scale, ranging from 0 (no impairment) to 5 (maximum impairment) with a scoring range of 0-40. Higher scores indicate greater disease impact. Question 5: (0) I am not limited doing any activities at home → (5) I am very limited doing activities at home CAT was self-completed at baseline, week 6 and week 12.

Time frame:
At week 6 and week 12
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline - CAT Individual Item (5, Activities) in the Full Analysis Set
units on a scaleEnsifentrine 3 mg BID
CAT question 5 (activities) at week 6 (mean change from baseline)-0.2 (-0.7 to 0.2)
CAT question 5 (activities) at week 12 (mean change from baseline)-0.3 (-0.8 to 0.1)
SecondaryMean Change From Baseline - CAT Individual Item (6, Confidence) in the Full Analysis Set

The COPD Assessment Test (CAT) is a one-page, 8-item questionnaire suitable for completion by patients diagnosed with COPD. When completing the questionnaire, individuals rate their experience on a 6-point scale, ranging from 0 (no impairment) to 5 (maximum impairment) with a scoring range of 0-40. Higher scores indicate greater disease impact. Question 6: (0) I am confident leaving my home despite my lung condition → (5) I am not at all confident leaving my home because of my lung condition CAT was self-completed at baseline, week 6 and week 12.

Time frame:
At week 6 and week 12
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline - CAT Individual Item (6, Confidence) in the Full Analysis Set
units on a scaleEnsifentrine 3 mg BID
CAT question 6 (confidence) at week 6 (mean change from baseline)0.1 (-0.5 to 0.8)
CAT question 6 (confidence) at week 12 (mean change from baseline)-0.2 (-0.8 to 0.4)
SecondaryMean Change From Baseline - CAT Individual Item (7, Sleep) in the Full Analysis Set

The COPD Assessment Test (CAT) is a one-page, 8-item questionnaire suitable for completion by patients diagnosed with COPD. When completing the questionnaire, individuals rate their experience on a 6-point scale, ranging from 0 (no impairment) to 5 (maximum impairment) with a scoring range of 0-40. Higher scores indicate greater disease impact. Question 7: (0) I sleep soundly → (5) I don't sleep soundly because of my lung condition CAT was self-completed at baseline, week 6 and week 12.

Time frame:
At week 6 and week 12
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline - CAT Individual Item (7, Sleep) in the Full Analysis Set
units on a scaleEnsifentrine 3 mg BID
CAT question 7 (sleep) at week 6 (mean change from baseline)0.0 (-0.5 to 0.5)
CAT question 7 (sleep) at week 12 (mean change from baseline)0.2 (-0.2 to 0.5)
SecondaryMean Change From Baseline - CAT Individual Item (8, Energy) in the Full Analysis Set

The COPD Assessment Test (CAT) is a one-page, 8-item questionnaire suitable for completion by patients diagnosed with COPD. When completing the questionnaire, individuals rate their experience on a 6-point scale, ranging from 0 (no impairment) to 5 (maximum impairment) with a scoring range of 0-40. Higher scores indicate greater disease impact. Question 8: (0) I have lots of energy → (5) I have no energy at all CAT was self-completed at baseline, week 6 and week 12.

Time frame:
At week 6 and week 12
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline - CAT Individual Item (8, Energy) in the Full Analysis Set
units on a scaleEnsifentrine 3 mg BID
CAT question 8 (energy) at week 6 (mean change from baseline)0.0 (-0.5 to 0.6)
CAT question 8 (energy) at week 12 (mean change from baseline)-0.2 (-0.7 to 0.2)

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ensifentrine 3 mg BID0/20 (0%)0/20 (0%)0/20 (0%)

Baseline characteristics

The full analysis set (FAS) included all subjects administered the study medication at visit 2 (day 1), and had a CAT completed at baseline and from at least one post-treatment visit.

Age, Continuous
Age, Continuous(years)Ensifentrine 3 mg BID
Median73 (57 to 79)
Sex: Female, Male
Sex: Female, Male(Participants)Ensifentrine 3 mg BID
Female8
Male10
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ensifentrine 3 mg BID
Hispanic or Latino0
Not Hispanic or Latino18
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ensifentrine 3 mg BID
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White18
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Ensifentrine 3 mg BID
United States18
Mean baseline CAT score
Mean baseline CAT score(units on a scale)Ensifentrine 3 mg BID
Mean18.3 ± 6.4
08

Study locations

1 site
  • Midwest Chest Consultants
    Saint Charles, Missouri 63301, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — There are no plans to make individual participant data available to other researchers.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Nov 2024, 5 months.

Results were first posted in Apr 2025, 4 months after primary completion.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 5 months is below that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2024
First posted
Jun 14, 2024
StartActual
Jun 11, 2024
Primary completionActual
Nov 26, 2024
CompletionActual
Dec 3, 2024
Results first posted
Apr 18, 2025
Last update
Apr 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06460493
Lead sponsor
Verona Pharma plc
Collaborators
Midwest Chest Consultants
Responsible party
Sponsor
First posted
Jun 14, 2024
Start date
Jun 11, 2024
Primary completion
Nov 26, 2024
Completion
Dec 3, 2024
Results posted
Apr 18, 2025
Last update
Apr 18, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ensifentrine

Start the discussion